Evidence map›Paper›PMID 42146446›Full record

ArticlebioRxiv : the preprint server for biology2026

IRES-TrAPPr reveals novel insights into viral and cellular mRNA translation.

Gemma E May, C Joel McManus

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gemma E MayDepartment of Biological Sciences, Carnegie Mellon University.
C Joel McManusDepartment of Biological Sciences, Carnegie Mellon University.ORCID 0000-0002-6605-2642

Funding

Regulation of mRNA translation by cis-acting sequences and trans-acting factorsR35GM145317 · NIGMS · CARNEGIE-MELLON UNIVERSITY · PI Charles Joel McManus · 2022 to 2026
$1.9M
NIGMS NIH HHS R35 GM145317
6 · The paper itself

Abstract

Ribosome recruitment to human mRNAs is thought to occur primarily via cap-dependent initiation (CDI). This process is suppressed during a variety of cellular stresses, including viral infection, suggesting stress-response genes and viral mRNAs use alternative mechanisms to initiate translation. Indeed, many viruses recruit ribosomes directly via Internal Ribosome Entry Sites (IRESes). Hundreds of human mRNAs have been reported to also contain IRESes due to their ability to enhance expression in bicistronic and backspliced circRNA plasmid reporters. These DNA-based screens also reported hundreds of novel IRESes from more than fifty human viruses. However, such assays are prone to false-positives due to promoter and splicing activity, do not compare CDI and IRES translation, and lack the temporal resolution necessary for stress-response studies. To address these issues, we developed IRES-Translating Affinity Protein Profiling (IRES-TrAPPr), a massively parallel reporter assay that simultaneously quantifies CDI and IRES activity from thousands of co-transfected mRNAs. We validated this new method using luciferase assays and structure-function analyses of established viral IRESes, demonstrating exquisite sensitivity and specificity. Using IRES-TrAPPr, we quantified the activities of IRES elements from hundreds of viruses from a diversity of hosts. Our results provide evidence that viral IRESes from warm-blooded hosts have adapted higher structural stability to maintain folding at higher temperatures. Finally, we find hundreds of candidate human and viral IRESes from DNA-based screens have negligible IRES activity. Altogether, our results show that IRES-TrAPPr provides a novel, accurate platform for IRES research.

Identifiers

PMID42146446
PMCPMC13174604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.